A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases
A Multi-centre Real-world Non-interventional Observational Study to Explore Prognoses of the Patients With Non-small Cell Lung Cancer Complicated With Oligometastases
1 other identifier
observational
1,000
1 country
10
Brief Summary
An observational study to explore prognoses and clinical treatments of the patients with non-small cell lung cancer complicated with oligometastases
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2017
Shorter than P25 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 31, 2017
CompletedFirst Submitted
Initial submission to the registry
February 2, 2018
CompletedFirst Posted
Study publicly available on registry
February 9, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2018
CompletedFebruary 9, 2018
February 1, 2018
4 months
February 2, 2018
February 7, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival
Overall survival
2014 - 2017
Secondary Outcomes (1)
Disease-free survival
2014 - 2017
Study Arms (1)
Patients with surgeries
NSCLC patients with surgeries
Interventions
Eligibility Criteria
Pathologically diagnosed patients with non-small cell lung cancer
You may qualify if:
- Pathologically diagnosed patients with non-small cell lung cancer;
- Tumor metastases in one organ (no more than 3 metastases);
You may not qualify if:
- Patients with intrapulmonary metastases or multiple primary tumors;
- Patients with pleural dissemination or invasion of extrapulmonary organs;
- Patients with supraclavicular lymph node metastasis;
- Patients with systematic diseases that would influence patient survivals;
- Patients with no records for visits;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tang-Du Hospitallead
- LinkDoc Technology (Beijing) Co. Ltd.collaborator
Study Sites (10)
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
China PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Henan cancer hospital
Zhengzhou, Henan, 450008, China
Tongji Hospital Affiliated to Huazhong Technology Hospital
Wuhan, Hubei, 430030, China
Jiangsu cancer hospital
Nanjing, Jiangsu, 210009, China
Xi'an Tangdu Hospital
Xi'an, Shaanxi, 710000, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Huaxi Hospital Affiliated to Sichuan University
Chengdu, Sichuan, 610041, China
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, 300051, China
First Hospital Affiliated to Zhejiang University
Hangzhou, Zhejiang, 310003, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 2, 2018
First Posted
February 9, 2018
Study Start
December 31, 2017
Primary Completion
April 30, 2018
Study Completion
April 30, 2018
Last Updated
February 9, 2018
Record last verified: 2018-02
Data Sharing
- IPD Sharing
- Will not share